These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11870541)

  • 1. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays.
    Bièche I; Olivi M; Noguès C; Vidaud M; Lidereau R
    Br J Cancer; 2002 Feb; 86(4):580-6. PubMed ID: 11870541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene.
    Bièche I; Parfait B; Tozlu S; Lidereau R; Vidaud M
    Carcinogenesis; 2001 Sep; 22(9):1521-6. PubMed ID: 11532875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
    Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A
    Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
    Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
    Breast Cancer Res; 2019 Feb; 21(1):34. PubMed ID: 30819233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
    Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
    Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.
    Takano Y; Takenaka H; Kato Y; Masuda M; Mikami T; Saegusa M; Okayasu I
    J Cancer Res Clin Oncol; 1999; 125(8-9):505-12. PubMed ID: 10480344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction.
    Bièche I; Franc B; Vidaud D; Vidaud M; Lidereau R
    Thyroid; 2001 Feb; 11(2):147-52. PubMed ID: 11288983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of ERBB family mRNA expression in breast carcinomas.
    Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
    Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas.
    Bièche I; Girault I; Sabourin JC; Tozlu S; Driouch K; Vidaud M; Lidereau R
    Br J Cancer; 2003 Mar; 88(6):863-70. PubMed ID: 12644823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer.
    Spyratos F; Andrieu C; Vidaud D; Briffod M; Vidaud M; Lidereau R; Bièche I
    Int J Biol Markers; 2000; 15(3):210-4. PubMed ID: 11012095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
    Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
    PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
    Bièche I; Parfait B; Laurendeau I; Girault I; Vidaud M; Lidereau R
    Oncogene; 2001 Dec; 20(56):8109-15. PubMed ID: 11781824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma.
    Wang MT; Chen G; An SJ; Chen ZH; Huang ZM; Xiao P; Ben XS; Xie Z; Chen SL; Luo DL; Tang JM; Lin JY; Zhang XC; Wu YL
    Dis Esophagus; 2012; 25(7):664-70. PubMed ID: 22150974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
    Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
    Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
    Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
    Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
    Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
    Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and Predictive Value of
    Jeffreys SA; Becker TM; Khan S; Soon P; Neubauer H; de Souza P; Powter B
    Front Endocrinol (Lausanne); 2022; 13():895729. PubMed ID: 35784572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.